Exagen (XGN) Preferred Stock Liabilities (2018 - 2019)

Exagen (XGN) reported Preferred Stock Liabilities of $121.0 million for Q2 2019, up 5.36% quarter-over-quarter from $114.9 million in Q1 2019.

Exagen (XGN) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

Exagen has reported Preferred Stock Liabilities for 2 years, with the latest figure at $121.0 million in Q2 2019.

For the quarter ending Q2 2019, Preferred Stock Liabilities changed N/A year-over-year to $121.0 million; the trailing twelve-month figure through Jun 2019 stood at $121.0 million (changed N/A YoY), and the FY2018 full-year result was $1.5 million, changed N/A from the prior year.
Preferred Stock Liabilities for Q2 2019 stood at $121.0 million, up from $114.9 million in the prior quarter.
The five-year high for Preferred Stock Liabilities was $121.0 million in Q2 2019, with the low at $1.5 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Waters	29,902.70 Bn	29,902.24 Bn	1.11 Bn	-
2	Thermo Fisher Scientific	175.99 Bn	172.74 Bn	7.74 Bn	-
3	Danaher	129.87 Bn	124.18 Bn	3.59 Bn	-
4	Idexx Laboratories	44.75 Bn	44.55 Bn	722.74 Mn	-
5	Agilent Technologies	37.52 Bn	35.72 Bn	990.00 Mn	-
6	Iqvia Holdings	30.91 Bn	28.94 Bn	1.36 Bn	-
7	Natera	30.21 Bn	29.11 Bn	696.04 Mn	-
8	Illumina	24.19 Bn	23.04 Bn	721.00 Mn	-
9	Mettler Toledo International	23.12 Bn	23.06 Bn	555.82 Mn	-
10	Exagen	101.38 Mn	79.87 Mn	10.21 Mn	-

Download Data